Abstract. Several biological properties of icariin have been identified, including its anticancer effect. However, the potential mechanisms underlying the effect of icariin on HepG2 hepatocellular carcinoma cells remain to be elucidated.
Introduction
Hepatocellular carcinoma (HCC) is the most common type of cancer in Southeast Asia and Southern Africa, and typically originates from hepatitis B or C virus-associated liver cirrhosis (1, 2) . The incidence of HCC in the US and Europe is also increasing (3, 4) . Chemotherapy is one of the most extensively used forms of anticancer treatment in China at present, alongside surgery and radiotherapy (5), however, due to the toxicity and side effects associated with currently available chemotherapeutic agents, improvements in treatment are required. Traditional Chinese medicines have long been consumed to prevent and treat various types of cancer, and several active compounds of Chinese medicinal herbs have been assessed for their anticancer effects (6, 7) .
Ic a r i i n i s a f l avo n ol g lyc o sid e, fo u n d i n Epimedium spp (Fig. 1) . A number of biological properties of icariin have been identified, including cardiovascular protection, a therapeutic effect in erectile dysfunction, and bone-strengthening and anti-hepatotoxic activities (8) (9) (10) (11) . Additionally, icariin increases lymphokine-activated killer cell and natural killer cell activity in patients with cancer (12) . Malignancy is a disorder involving an imbalance of cell proliferation, differentiation and apoptosis. A study by Shi et al (13) reported that icariin exerts an antiproliferative effect on HepG2-bearing nude mice. Furthermore, tumor cell invasion and migration are driven by continuous remodeling of the actin cytoskeleton, which also provides cellular structure and polarization (14) , and is a potential therapeutic target in tumor cells. Therefore, the present study evaluated the anticancer effects of icariin on HepG2 cells, focusing on its effects on proliferation, apoptosis and the actin cytoskeleton. Cell culture. Human HepG2 cells were cultured in DMEM-H supplemented with 10% FBS, penicillin G (100 U/ml) and streptomycin (100 µg/ml) in a humidified atmosphere with 5% CO 2 and 95% air at 37˚C. When the cells reached 80% confluence, after 3 days of culture, they were passaged. The adherent cells were washed and detached using 1 ml 0.25% trypsin-EDTA solution for 2 min. The resuspended cells were then placed into three cell culture flasks for incubation under the same conditions.
Materials and methods

Antibodies
Cell proliferation. The effect of icariin on HepG2 cell proliferation was determined using an MTT assay. Briefly, the HepG2 cells were seeded in 96-well plates at a density of 1x10 , 10 −7 or 10 −8 mol/l) for periods of 24, 48 and 72 h. Subsequently, 10 µl MTT (5 mg/ml) was added to each well and the the plates were incubated at 37˚C for an additional 4 h. The resulting formazan crystals were solubilized by adding 100 µl DMSO to each well for 20 min. When the crystals had fully dissolved, the plates were read on a micro-plate reader (iMark; Bio-Rad Laboratories Inc., Hercules, CA, USA) at a wavelength of 490 nm. The concentration of drug required to inhibit 50% of cell growth (IC 50 ) was calculated.
Cell cycle analysis. Once the optimal conditions of icariin treatment of HepG2 cells had been established (10 -5 M for 72 h), cell cycle analysis was performed on the three flasks of cells cultured with either 10% FBS, oxaliplatin (10 mg/l), or icariin (10 −5 mol/l) for 72 h. The cells were digested using trypsin-EDTA solution, and the resuspended cells were counted (1x10 6 per flask). The cells were fixed with 70% ethanol at -20˚C overnight, washed twice with PBS and incubated with RNaseA (100 mg/ml) in PBS at room temperature for 30 min. The DNA was labeled in the dark using propidium iodide (50 mg/ml) and then washed, following which the cells were analyzed using a FACScalibur flow cytometer (BD Biosciences, San Diego, CA, USA). ) were added for 72 h, following which the plates were washed and the cells were fixed with 95% ethanol for 15 min. The cells were then washed again, and incubated in blocking buffer for 15 min at 37˚C to prevent non-specific antibody binding. The cells were then incubated in anti-Bcl-2 antibody (1:500) for 1 h at 37˚C, and in secondary antibody (1:2,000) for 20 min at room temperature, prior to a final washing step. Staining was visualized using DAB, and nuclei were counterstained with hematoxylin.
Western blot analysis. The cells were seeded in a 2.5 cm 2 culture flask. After 24 h, the cells were incubated with FBS (10%), oxaliplatin (10 mg/l) or icariin (10 −5 mol/l −1 ). After 3 days, the cells were washed with ice-cold PBS and subsequently lysed using a mammalian tissue protein extraction kit (RIPA Lysis Buffer kit; Boster Biological Technology Co. Ltd., Wuhan, China) containing 1 mM phenylmethanesulfonyl fluoride protease inhibitor. The cells were centrifuged at 12,000 x g for 10 min at 4˚C, and the supernatants were collected. The protein concentration was determined using a bicinchoninic acid kit (Ding Guo, Beijing, China). Equal quantities (50 µg) of protein in the cell extracts were separated on denatured 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels (Ding Guo) and the proteins were transferred onto polyvinylidene difluoride membranes (Immobilon; EMD Millipore, Danvers, MA, USA). The membranes were blocked in blocking buffer [5% (w/v) non-fat dry milk (Yi Li, Inner Mongolia, China) in Tris-buffered saline containing 0.1% Tween20 (Boster, Wuhan, China) (TBST)] at 37˚C for 60 min and then incubated with anti-Bcl-2 (1:800) or anti-GAPDH antibody (1:1,000) overnight at 4˚C. Following four washes with TBST, the membranes were incubated with HRP-conjugated secondary antibody (1:2,000; Protein Tech Group, Inc, Chicago, USA) for 1 h at 37˚C. The membranes were then washed five times with TBST. Finally, the immunoblot signals were visualized using enhanced chemiluminescence reagent (TransGen, Beijing, China). Quantification of proteins was performed using an EC3 Chemi HR 410 imaging system (UVP, Inc., Cambridge, UK).
Confocal microscopic analysis of F-actin.
The cells were incubated in confocal plates at a density of 1x10 3 cells per plate. After 3 days, the cells were washed and fixed with 95% ethanol for 15 min, followed by another wash. For imaging analysis of the F-actin filaments, the HepG2 cells were stained with phalloidin-fluorescein isothiocyanate (FITC; 50 mg/l; Invitrogen Life Technologies, Carlsbad, CA, USA) in the dark for 20 min, prior to three washes in PBS. Finally, the samples were analyzed using a confocal laser scanning microscope (Model FV500; Olympus, Tokyo, Japan). Images were captured and quantified using FluoView software (Olympus).
Statistical analysis.
One-way analysis of variance followed by Tukey's post-hoc comparison was used to compare groups. All data are expressed as the mean ± standard error of the mean. P<0.05 was considered to indicate a statistically significant difference. Each experiment was repeated at least three times.
Results
Icariin inhibits HepG2 cell proliferation.
The antiproliferative property of icariin in cultured HepG2 cells was determined using an MTT assay. Icariin significantly inhibited the proliferation of the HepG2 cells at concentrations between 10 −4 and 10 −8 mol/l (Fig. 2) . The IC 50 was observed at ~10 −5 mol/l at 72 h, therefore, this concentration was selected for use in the subsequent experiments.
Icariin arrests HepG2 cell cycle at the G 0 /G 1 phase. The oxaliplatin group and the icariin group exhibited significantly higher proportions of the cell population in the G 0 /G 1 phase, compared with the control group (P<0.05; Fig. 3 ). The proportion of HepG2 cells in the oxaliplatin (24.19%) and icariin (21.07%) groups at the S phase were significantly lower, compared with that in the control group (28.62%; P<0.05 and P<0.01, respectively). No significant difference in cell cycle distribution was observed between the oxaliplatin and icariin groups.
Icariin inhibits the expression of Bcl-2. Bcl-2, an anti-apoptotic molecule, can be used as a marker for cell apoptosis. Therefore, the presents study examined expression of Bcl-2 in HepG2 cells using immunocytochemical and western blot analyses. The expression levels of Bcl-2 were significantly lower in the oxaliplatin and icariin groups, compared with the control group (P<0.01; Fig. 4) . Furthermore, the expression of Bcl-2 in the icariin-treated cells was lower than that in the oxaliplatin-treated cells (P<0.01). Western blot analysis confirmed the results of the immunohistochemical analysis, with a lower expression level of Bcl-2 observed in the oxaliplatin and icariin groups, compared with the control (P<0.05 and P<0.01, respectively; Fig. 5 ). Icariin treatment led to a sharp decrease in the protein expression of Bcl-2, compared with oxaliplatin treatment (P<0.01).
Disruption of F-actin by icariin.
Confocal microscopy was used to determine the effects of icariin on F-actin in the HepG2 cells (Fig. 6 ). In the untreated HepG2 cell control group, long-form and regular F-actin filaments were observed, however, polymerization of F-actin filaments was noticeably disrupted following 3 days of exposure to either oxaliplatin or icariin.
Discussion
Icariin, the major component of Herba epimedii, is reported to exhibit several biological activities with no clear side effects (15) . The results of the present study demonstrated that, in human HepG2 cells, icariin inhibited the proliferation, affected the cell cycle and cell apoptosis, and disrupted the F-actin cytoskeleton. Previous studies have investigated the antiproliferative efficacy of icariin on HepG2 cells and the possible underlying mechanism (13, 16) . It is well known that DNA damage can induce G 1 phase arrest. Previous studies have demonstrated that cell cycle arrest at the G 0 /G 1 phase can inhibit the proliferation of HepG2 cells (17, 18) . In the present study, exposure to icariin (10 −5 mol/l for 72 h) significantly increased the proportion of cells in the G 0 /G 1 phase and decreased the proportion of cells in the S phase, indicating that icariin inhibited proliferation and prevented the cells from entering the S phase.
Apoptosis is regulated by two major pathways: The death receptor-induced extrinsic pathway and the mitochondria-apoptosome-mediated intrinsic pathway (19) . Bcl-2 family proteins are central in controlling the mitochondrial pathway, and >20 members of this family have been identified, including Bcl-2, which is one of the proteins that suppresses apoptosis (20) . The overexpression of Bcl-2 causes HepG2 cells to become resistant to the induction of apoptosis, possibly by preventing the release of cytochrome c (21) . In the present study, icariin significantly decreased the protein expression of Bcl-2, indicating that it may promote the apoptosis of HepG2 cells by suppressing the protein expression of Bcl-2.
The cytoskeleton is the internal framework of a cell and is largely composed of actin microfilaments, in addition to microtubules and intermediate filaments. Actin is important in the maintenance of cell pattern and tight junctions between cells (22) (23) (24) . The balance between microfilament dissociation and polymerization regulates the movement, adhesion and fission of cells (25, 26) . F-actin has been used as a sensitive index in the assessment of the development of tumor cells in certain types of early phase cancer (27) (28) (29) . In the present study, treatment of the HepG2 cells with icariin significantly decreased polymerization of the F-actin cytoskeletons. Thus, it is possible that icariin suppresses the development of HepG2 cells by acting on the microfilament, and it is suggested that F-actin may be important in HepG2 cells.
In conclusion, the present study demonstrated that, at an optimal concentration of 10 −5 mol/l, icariin inhibited the proliferation of HepG2 cells, promoted their apoptosis by enhancing the protein expression of Bcl-2 and, importantly, suppressed polymerization of the F-actin cytoskeleton in the HepG2 cells. Therefore, icariin offers promise as a novel therapeutic agent in the treatment of HCC.
